Table 1.
Characteristics of included studies
| Author | Zoccali (− 14) | Lundwall 2 μg (− 15) | Lundwall 1 μg (− 15) | Theti (− 15) | Kumar (− 17) |
|---|---|---|---|---|---|
| Country | Italy | Sweden | Sweden | USA | India |
| Duration | 12 w | 12 w | 12 w | 12 w | 16 w |
| Sample size (nr) | 89, analysis on 88 | 24, ITT | 24, ITT | 60, 55 completed, analysis on 46 | 120, analysis on 117 |
| CKD stage | 3–4 | 3–4 | 3–4 | 3–4 | 3–4 |
| Treatment | paricalcitol | paricalcitol | paricalcitol | paricalcitol | Cholecalciferol |
| Dose | 2 μg daily | 2 μg daily | 1 μg daily | 1 μg daily | 300.000 IU at baseline and after 8 week |
| Baseline 25 (OH) D(nmol/l) | 35.5 | 65.1 | 66.7 | 1.25-OHD: 34.5 (pg/ml) | 33.2 |
| Age (mean) | 62.5 | 65.0 | 68.6 | 62.5 (median) | 44.2 |
| ACEi/ARB (%) | N/A | 80.6 | 80.6 | 69.1 | 67.5 |
| Jadad score | 4 | 4 | 4 | 3 | 5 |
| Underlying condition/DM | N/A | Non-diabetic patients | Non-diabetic patients | Diabetic nephropathy | Non-diabetic patients |
| Outcome | FMD | FMD,PWV,echo,iontophoresis,microcirculation | FMD,PWV,echo,iontophoresis,microcirculation | FMD | FMD,PWV |
ITT intention to treat, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, FMD flow mediated vasodilation, PWV pulse wave velocity, Echo echocardiography